July 30, 2018 10:32 AM EDT

Redhill spikes — briefly — on positive Crohn's data; Daiichi inks global licensing deal with Glycotope

John Carroll

Editor & Founder

→ Shares of Israel’s Redhill BioPharma $RDHL spiked Monday morning — then quickly began to slide back — after the biotech laid out data demonstrating how …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Redhill spikes — briefly — on positive Crohn's data; Daiichi inks global licensing deal with Glycotope

John Carroll

Editor & Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Summit’s disappointing survival readout raises stakes for full data

Summit says bispecific misses overall survival in closely-watched lung cancer study

HHS says it's pulled Covid shot guidance for healthy kids. The CDC vaccine schedule shows otherwise

Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech

Sanofi, Regeneron report underwhelming COPD data for IL-33 antibody, shares drop

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Red­hill spikes — briefly — on pos­i­tive Crohn's da­ta; Dai­ichi inks glob­al li­cens­ing deal with Gly­co­tope

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Redhill spikes — briefly — on positive Crohn's data; Daiichi inks global licensing deal with Glycotope